BioXcel Therapeutics Announces Executive Changes and Wind-Down Process
BioXcel Therapeutics terminated four officers and appointed Samir Saleem as president and secretary as part of a company wind-down.
Stocks · News reference
Teva Completes Acquisition of Neuroscience Assets from BioXcel Therapeutics
Teva Pharmaceuticals International GmbH has acquired worldwide rights to BXCL501 and IGALMI from BioXcel Therapeutics, Inc. through a court-supervised bankruptcy sale.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.
Why Samsara Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Samsara jumped 14.8% premarket after Q2 results beat estimates; several stocks surged, while DSS plunged 36.4% on a proposed offering.
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
8-K filing — BioXcel Therapeutics, Inc. (BTAI)
Filed: 2026-09-01 AccNo: 0001104659-26-104106 Size: 205 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 Billion, BioXcel Bankruptcy
Major M&A deals this week include: The Descartes Systems buys Tai, KKR nabs Ci FLAVORS, Skimmer Acquires Pool Builder Geek and Poologics.